Tagged Content

Tags > Medication Updates
Year: Medication:  Abilify (aripiprazole) Addyi Antipsychotics Aripiprazole Aristada Belsomra Brintellix Buprenorphine and naloxone Probuphine Clozapine Chantix and Zyban Cymbalta Daytrana Diazepam Effexor Farxiga Fentanyl and Opioids Geodon Hysingla ER Ingrezza Lamictal (lamotrigine) Lorazepam Lucemyra (lofexidine hydrochloride) Lunesta Methylphenidate Naloxone/Evzio Naltrexone Olanzapine Olanzapine/Zyprexa Opana ER Opioids Opioids and Benzodiazepines UPDATE: Opioids and Benzodiazepines Rexulti Strattera Sublocade Tanzeum Targiniq ER Tramadol Treatment for Alcohol Use Disorder Vraylar Vynase Ziprasidone Zolpidem Zyprexa General Resources:   DEA Pharmacists' Manual FDA Medication Updates NIMH Mental Health Medications Guide         2018 FDA warns about immune system reaction with Lamictal (lamotrigine) This can cause severe inflammation throughout the body and lead to hospitalization and death, especially if the reaction is not diagnosed and treated quickly.  FDA approves Lucemyra for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. Drug may lessen the severity of withdrawal symptoms, but may not completely prevent them and is only approved for treatment for up to 14 days.



View all tags
View RSS XML
AMERICAN PSYCHIATRIC NURSES ASSOCIATION and APNA-Logoare registered in the U.S. Patent and Trademark Office as trademarks of the American Psychiatric Nurses Association.
The American Psychiatric Nurses Association is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.